NCT06836232View on ClinicalTrials.gov

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 28, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Recurrent Pericarditis
Interventions
DRUG

VTX2735

Dose A, daily

DRUG

VTX2735

Dose B, Daily

DRUG

VTX2735

Dose C, daily

Trial Locations (15)

22908

RECRUITING

Local Site #840018, Charlottesville

23219

RECRUITING

Local Site #840004, Richmond

32086

RECRUITING

Local Site #840016, Saint Augustine

42303

WITHDRAWN

Local Site #840011, Owensboro

44195

RECRUITING

Local Site #840017, Cleveland

55905

RECRUITING

Local Site #840005, Rochester

60068

RECRUITING

Local Site #840002, Park Ridge

60611

RECRUITING

Local Site #840008, Chicago

77030

RECRUITING

Local Site #840019, Houston

77034

RECRUITING

Local Site #840001, Houston

84132

RECRUITING

Local Site #840013, Salt Lake City

85718

RECRUITING

Local Site #840012, Tucson

92868

RECRUITING

Local Site #840014, Orange

98105

RECRUITING

Local Site #840021, Seattle

02114

RECRUITING

Local Site #840010, Boston

All Listed Sponsors
lead

Zomagen Biosciences Ltd.

INDUSTRY